Author

N. Nagathihalli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Organism:mouse· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Bianchi· 3 shared A. R. Dosch· 3 shared J. Datta· 3 shared N. Merchant· 3 shared S. Mehra· 3 shared S. Singh· 3 shared Y. Ban· 3 shared I. De Castro Silva· 2 shared

Activity by Year

2020-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Bianchi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CREB drives acinar cells to ductal reprogramming and promotes pancreatic cancer progression in preclinical models of alcoholic pancreatitis

S. Srinivasan, S. Mehra, S. Jinka, A. Bianchi, S. Singh, A. R. Dosch, H. Amirian, V. Krishnamoorthy, I. D. C. Silva, M. Patel, E. W. Box, V. Garrido, T. M. Totiger, Z. Zhou, Y. Ban, , N. Nagathihalli

This study shows CREB promotes acinar-to-ductal reprogramming and pancreatic cancer progression in alcoholic pancreatitis models by enhancing fibrosis and tumor growth.

Cellular and Molecular Gastroenterology and Hepatology · Jan 1, 2025Peer-reviewedCancer Biology

Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with KRAS-TP53 Co-Alteration in Pancreatic Cancer

J. Datta, A. Bianchi, I. De Castro Silva, N. U. Deshpande, L. L. Cao, S. Mehra, S. Singh, C. Rafie, X. Sun, X. Chen, X. Dai, A. Colaprico, P. Sharma, A. R. Dosch, A. Pillai, , N. B. Merchant

bioRxiv · May 1, 2022Cancer Biology

Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancer

J. Datta, X. Dai, A. Bianchi, I. De Castro Silva, S. Mehra, V. T. Garrido, P. Lamichhane, S. Singh, Z. Zhou, A. R. Dosch, F. Messagio, Y. Ban, O. Umland, P. J. Hosein, N. Nagathihalli, N. Merchant

This paper shows that combining MEK and STAT3 inhibitors reprograms stromal inflammation and enhances immunotherapy response in pancreatic cancer.

bioRxiv · Mar 7, 2021 · PreprintCancer Biology

Stroma secreted IL6 selects for stem-like population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways

K. Kesh, V. T. Garrido, A. Doesch, B. Durden, V. K. Gupta, N. S. Sharma, M. Lyle, N. Nagathihalli, N. Merchant, A. Saluja, S. Banerjee

This study shows that stromal IL6 promotes stem-like cells and metabolic reprogramming in pancreatic tumors, creating an immune-evasive microenvironment that can be targeted to improve checkpoint inhibitor therapy.

Cell Death & Disease · Nov 11, 2020Peer-reviewedCancer Biology